Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Definiens AG. (11/7/16). "Press Release: Definiens Launches Cloud-based Digital Pathology Solution VeriTrova to Support Takeda’s Translational and Biomarker Research Efforts". Munich.

Organisations Organisation Definiens AG
  Group AstraZeneca (Group)
  Organisation 2 Takeda Pharmaceutical Co., Ltd. (TSE: 4502)
  Group Takeda (Group)
Products Product VeriTrova™ cloud-based digital pathology solution
  Product 2 cancer drug
Index term Index term Takeda–AstraZeneca: digital pathology, 201611– collab using Definiens' newly launched VeriTrova cloud-based solution
Persons Person Colarusso, Thomas (Definiens 201106 VP Sales + Operations at Definiens Inc.)
  Person 2 Baratta, Melissa (Affect PR 201505)
     


New Solution Helps Accelerate Clinical Trials


Definiens, the leader in Tissue Phenomics® solutions from biomarker discovery to meaningful diagnostics, today announced a program collaboration with Takeda Pharmaceuticals to enable comprehensive tissue-based analysis in clinical trials.

Definiens’ products and services deepen the understanding of disease biology and the immune system to advance clinical trials. By using knowledge-driven biomarker analysis in combination with VeriTrova™, the company’s new cloud-based digital pathology platform, Definiens seamlessly translates research to clinical knowledge to the next generation of diagnostics.

As an early adopter of Definiens’ VeriTrova, Takeda will have the opportunity to leverage the platform to support its development programs.

“VeriTrova accelerates clinical trials through remote uploading and viewing of digitized IHC images from wet-lab partners and CROs to the cloud, where the images are analyzed,” says Thomas Colarusso, VP Business Development and Strategy at Definiens.

The real-time analysis is expected to help Takeda reduce normal processes from months to weeks, with image analysis providing a more automated and standardized readout.

“Takeda is dedicated to operational excellence and delivering high quality results in our clinical studies,” says Andrew Dorner, VP and Global Head of Translational Medicine at Takeda. “We expect this system will improve the timelines and quality of our image analysis for clinical biomarkers.”

For more information about Definiens, visit www.definiens.com.


About Definiens

We improve patient lives by unlocking the tissue phenome. In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.

Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.


Media Contacts

Affect
Melissa Baratta
+1 212-398-9680
mbaratta@affect.com

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top